Inhibitory kappa B alpha expression in endometriosis

Other OA: gold CC0
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-22 ⓘ

This letter discusses the findings of Arlier et al. regarding reduced IκB expression in endometriosis, questioning methodological details and suggesting future research into IκB as a therapeutic target.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-22 · read from full text ⓘ

The paper discusses prior laboratory findings by Arlier et al. on how estradiol modulates TNF-α and IL-1α–induced phosphorylation and degradation of inhibitory κB alpha (IκB) in endometrial cells, noting that ectopic endometrium showed less IκB immunoreactivity and that NF-κB activity may be relevant to endometriosis-associated inflammation, angiogenesis, proliferation, and reduced apoptosis. It argues that the study’s reported ectopic tissue samples (n=6) lack key methodological details, including disease severity by ASRM classification and the anatomical sources of implants, such as peritoneal, ovarian, or deep infiltrating endometriosis. The commentary suggests that IκB activity and estradiol effects might differ across endometriosis phenotypes, which could reflect different pathogeneses. This paper is centrally about endometriosis — it focuses on IκB expression and estradiol regulation in ectopic endometrial tissue and highlights methodological considerations specific to endometriosis implant subtypes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,763 characters · extracted from pmc-nxml · 1 sections · click to expand

To

We read with great interest the article by Arlier et al. ( 1 ) entitled “Tumor necrosis factor alfa and interleukin 1 alfa-induced phosphorylation and degradation of inhibitory kappa B (IкB), alfa are regulated by estradiol (E 2 ) in endometrial cells,” published in your journal. Interestingly, the authors demonstrated that ectopic endometrium was significantly characterized by less immunoreactivity for IкB, a cytoplasmatic inhibitor of the transcription factor nuclear factor (NF)-кB, and that E 2 might modulate its expression. The rational of this study is based on evidence of the critical role of NF-кB, which mediates gene transcription of several protein involved in inflammation, angiogenesis, as well as in proliferation and reduced apoptosis of endometriotic cells. A previous study reported that an excessive activation of NF-кB might be present in endometriotic implants of women affected by endometriosis ( 2 ) . For this reason, it might represent an interesting target for treating this benign chronic hormonal-dependent disease ( 3 ) . Although the authors should be congratulated for their laboratory findings, we would like to discuss some methodologic concerns of their study. In the material and methods, the authors described that the ectopic endometrial samples for western blot and immunocytochemical analysis were obtained from 6 women with endometriosis. First, the authors should add information on the severity of endometriosis for each patient in accordance with American Society of Reproductive Medicine classification. More importantly, the authors did not report from which sites the endometriotic implants were obtained, and in particular, if they originated from peritoneal nodules, ovarian endometriomas or deep infiltrating endometriosis (DIE) nodules. In general, it would be of particular interest to know if the activity of IкB and the effect of E 2 on its expression would be different in implants originating from these three distinguished phenotypes of endometriosis, which probably have different pathogeneses ( 4 ) . Regarding this aspect, it has been previously described that nodules of DIE may have higher proinflammatory reaction, higher vascularization, as well a higher density of nerve fibers, which may be responsible for a more aggressive clinical behavior ( 5 ) . Nevertheless, the results of the study by Arlier et al. ( 1 ) are innovative and promising. Thus, in the near future, new studies are needed to better clarify the role IкB in inflammatory pathway of endometriotic cells. More importantly, it could be advisable to better understand if this protein may represent a suitable molecular target for a chronic medical therapy, which needs to balance clinical efficacy with cost and tolerability.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (6)

Source provenance

europepmc
last seen: 2026-10-17T06:09:56.316927+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:23:47.170672+00:00
License: CC0 · commercial use OK